TISIDB

Summary
Symbol	HORMAD1
Name	HORMA domain containing 1
Aliases	DKFZP434A1315; CT46; cancer/testis antigen 46; NOHMA; newborn ovary HORMA protein; HORMA domain-containing p ......
Chromosomal Location	1q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Chromosome Note=Preferentially localizes to unsynapsed or desynapsed chromosomal regions during the prophase I stage of meiosis. TRIP13 is required for depletion from synapsed chromosomes. The expression of the phosphorylated form at Ser-377 is restricted to unsynapsed chromosomal regions (By similarity).
Domain	PF02301 HORMA domain
Function	Plays a key role in meiotic progression. Regulates 3 different functions during meiosis: ensures that sufficient numbers of processed DNA double-strand breaks (DSBs) are available for successful homology search by increasing the steady-state numbers of single-stranded DSB ends. Promotes synaptonemal-complex formation independently of its role in homology search. Plays a key role in the male mid-pachytene checkpoint and the female meiotic prophase checkpoint: required for efficient build-up of ATR activity on unsynapsed chromosome regions, a process believed to form the basis of meiotic silencing of unsynapsed chromatin (MSUC) and meiotic prophase quality control in both sexes.

> Gene Ontology [ TOP ]
Biological Process	GO:0000075 cell cycle checkpoint GO:0000819 sister chromatid segregation GO:0001701 in utero embryonic development GO:0001824 blastocyst development GO:0007059 chromosome segregation GO:0007062 sister chromatid cohesion GO:0007126 meiotic nuclear division GO:0007127 meiosis I GO:0007129 synapsis GO:0007130 synaptonemal complex assembly GO:0007135 meiosis II GO:0007281 germ cell development GO:0007283 spermatogenesis GO:0007292 female gamete generation GO:0010639 negative regulation of organelle organization GO:0010948 negative regulation of cell cycle process GO:0022412 cellular process involved in reproduction in multicellular organism GO:0033313 meiotic cell cycle checkpoint GO:0040020 regulation of meiotic nuclear division GO:0042138 meiotic DNA double-strand break formation GO:0045132 meiotic chromosome segregation GO:0045143 homologous chromosome segregation GO:0045144 meiotic sister chromatid segregation GO:0045786 negative regulation of cell cycle GO:0045835 negative regulation of meiotic nuclear division GO:0048232 male gamete generation GO:0048477 oogenesis GO:0051177 meiotic sister chromatid cohesion GO:0051321 meiotic cell cycle GO:0051445 regulation of meiotic cell cycle GO:0051447 negative regulation of meiotic cell cycle GO:0051598 meiotic recombination checkpoint GO:0051783 regulation of nuclear division GO:0051784 negative regulation of nuclear division GO:0051983 regulation of chromosome segregation GO:0060629 regulation of homologous chromosome segregation GO:0060631 regulation of meiosis I GO:0070192 chromosome organization involved in meiotic cell cycle GO:0070193 synaptonemal complex organization GO:0090305 nucleic acid phosphodiester bond hydrolysis GO:0098813 nuclear chromosome segregation GO:1903046 meiotic cell cycle process GO:2000241 regulation of reproductive process GO:2000242 negative regulation of reproductive process
Molecular Function	-
Cellular Component	GO:0000793 condensed chromosome GO:0000794 condensed nuclear chromosome GO:0000795 synaptonemal complex GO:0044454 nuclear chromosome part

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	HORMAD1
Name	HORMA domain containing 1
Aliases	DKFZP434A1315; CT46; cancer/testis antigen 46; NOHMA; newborn ovary HORMA protein; HORMA domain-containing p ......
Chromosomal Location	1q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between HORMAD1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	HORMAD1
Name	HORMA domain containing 1
Aliases	DKFZP434A1315; CT46; cancer/testis antigen 46; NOHMA; newborn ovary HORMA protein; HORMA domain-containing p ......
Chromosomal Location	1q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of HORMAD1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	HORMAD1
Name	HORMA domain containing 1
Aliases	DKFZP434A1315; CT46; cancer/testis antigen 46; NOHMA; newborn ovary HORMA protein; HORMA domain-containing p ......
Chromosomal Location	1q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of HORMAD1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.198	0.733
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.113	0.905
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.448	0.55
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.024	0.968
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.414	0.703
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.573	0.665
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	2.136	0.0254
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	2.318	0.0877
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	2.159	0.136
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.447	0.362
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.447	0.529
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.049	0.894

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of HORMAD1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	HORMAD1
Name	HORMA domain containing 1
Aliases	DKFZP434A1315; CT46; cancer/testis antigen 46; NOHMA; newborn ovary HORMA protein; HORMA domain-containing p ......
Chromosomal Location	1q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HORMAD1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	HORMAD1
Name	HORMA domain containing 1
Aliases	DKFZP434A1315; CT46; cancer/testis antigen 46; NOHMA; newborn ovary HORMA protein; HORMA domain-containing p ......
Chromosomal Location	1q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HORMAD1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HORMAD1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	HORMAD1
Name	HORMA domain containing 1
Aliases	DKFZP434A1315; CT46; cancer/testis antigen 46; NOHMA; newborn ovary HORMA protein; HORMA domain-containing p ......
Chromosomal Location	1q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HORMAD1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	HORMAD1
Name	HORMA domain containing 1
Aliases	DKFZP434A1315; CT46; cancer/testis antigen 46; NOHMA; newborn ovary HORMA protein; HORMA domain-containing p ......
Chromosomal Location	1q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of HORMAD1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	HORMAD1
Name	HORMA domain containing 1
Aliases	DKFZP434A1315; CT46; cancer/testis antigen 46; NOHMA; newborn ovary HORMA protein; HORMA domain-containing p ......
Chromosomal Location	1q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between HORMAD1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	HORMAD1
Name	HORMA domain containing 1
Aliases	DKFZP434A1315; CT46; cancer/testis antigen 46; NOHMA; newborn ovary HORMA protein; HORMA domain-containing p ......
Chromosomal Location	1q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting HORMAD1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse HORMAD1